Malaria persists as an undiminished global problem, but the resources available to address
it have increased. Many tools for understanding its biology and epidemiology are well …

Background Surrogate markers of protective immunity to malaria in humans are needed to
rationalize malaria vaccine discovery and development. In an effort to identify such markers …

One goal in sequencing the Plasmodium falciparum genome, the agent of the most lethal
form of malaria, is to discover vaccine and drug targets. However, identifying those targets in …

Malaria vaccine discovery and development follow two principal strategies. Most subunit
vaccines are designed to mimic naturally acquired immunity that develops over years upon …

Background Plasmodium falciparum merozoite surface protein (MSP) 3 is an asexual blood-
stage malaria vaccine candidate antigen. Sequence polymorphisms divide alleles into 2 …

Background Malaria vaccines based on the 19-kDa region of merozoite surface protein 1
(MSP-119) derived from the 3D7 strain of Plasmodium falciparum are being tested in clinical …

Plasmodium vivax apical membrane antigen 1 (PvAMA-1) is an important malaria vaccine
candidate. We present the first comprehensive analysis of nucleotide diversity across the …

The present study examined the genetic diversity and population structure of Plasmodium
falciparum in western Kenya by analyzing the polymorphism of 12 microsatellite loci and two …

We investigated the genetic diversity of the 42kDa fragment of the merozoite surface protein
1 (MSP-1) antigen in Plasmodium falciparum and P. vivax, as well as in non-human primate …

Merozoite surface protein 1 of Plasmodium vivax (PvMSP-1), a major target for malaria
vaccine development, contains six highly polymorphic domains interspersed with conserved …